Join us as Lawrence Sherman speaks with Dr. Mark Freedman on immunomodulators in multiple sclerosis and the need for patient-centric care. STATEMENT: As of August 2018, Cladribine was approved in Europe for the treatment of highly active relapsing multiple sclerosis (RMS). All studies presented in this education are still accurate. To learn more about this approval, click here.